Breath Biopsy PAN Cancer Trial featured in OneNucleus
Published on: 2 Nov 2017, under Breath Biopsy
The Breath Biopsy® PAN Cancer Trial, a collaboration between Owlstone Medical and Cancer Research UK (CRUK) was featured in the Autumn issue of OneNucleus Highlights. You can read the article below:
Owlstone Medical and CRUK Initiate PAN Cancer Clinical Trial to Evaluate Breath Biopsy for Early Detection of Disease
Owlstone Medical is developing a breathalyser for disease and recently announced the initiation of the PAN Cancer trial for Early Detection of Cancer in Breath. The large scale clinical study will evaluate the use of the company’s Breath Biopsy platform for the early detection of multiple cancer types.
The PAN Cancer trial is being conducted in collaboration with a team of leading cancer researchers at the Cancer Research UK (CRUK) Cambridge Centre, the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust. The Chief Investigator is Professor Rebecca Fitzgerald, who is co-lead of the CRUK Cambridge Centre Early Detection Programme, Professor of Cancer Prevention at the MRC Cancer Unit, and an Honorary Consultant in Gastroenterology and General Medicine at Addenbrooke’s Hospital, Cambridge.
The PAN Cancer trial aims to develop Breath Biopsy tests for the early detection of bladder, breast, head and neck, kidney, oesophageal, pancreatic and prostate cancers and brain tumours, with the ultimate aim of detecting cancer much earlier, when better treatment options are available and more lives can be saved.
Professor Rebecca Fitzgerald, the study’s Chief Investigator said: ‘New tools that can help to diagnose cancer earlier are urgently needed and we are very pleased to collaborate with Owlstone Medical to evaluate Breath Biopsy for early detection. The PAN Cancer trial forms part of our Early Detection Programme, a flagship initiative of the CRUK Cambridge Centre that aims to devise better means of detecting cancer and diagnosing it in the early stages, which can lead to improved outcomes for cancer patients.’
Billy Boyle, co-founder and CEO at Owlstone Medical, commented: ‘Positive results from the PAN Cancer trial could be game-changing in the fight against cancer: Breath Biopsy tests for cancer detection and diagnosis have the potential to greatly improve survival across a range of cancers. Our Breath Biopsy platform is already being assessed in large scale clinical trials for the non-invasive, early detection of lung and colon cancer, and it will be exciting to see how its use can be extended to other cancer types. Success in this study would make a real difference to the lives of millions of people, and supports our vision of saving 100,000 lives and $1.5 billion in healthcare costs.’
‘We are very proud to have the opportunity to work with these world leading research teams on this ground breaking trial, which could have a great impact on improving cancer survival.’
You can download the complete OneNucleus Highlights as pdf here:
If you want to learn more about how Owlstone Medical’s Breath Sampling and Analysis technology and Services are being utilized in early detection and precision medicine, why not download our free ebook: Breath Biopsy: The Complete Guide?